# ICON 30 FAF FOR OUTDOOR ACTIVITIES



# NEW PRODUCT

### ICON 30 FAF THE LIGHTWEIGHT WHEELCHAIR





### **STABLE AND RELIABLE**

The ICON 30 FAF is an extremely stable wheelchair that can be used for outdoor activities. The foldable wheelchair with its fixed anterior frame (FAF) offers several adjustment possibilities and can therefore be adjusted to the needs of its user. Depending on the user's activity level, different levels of adjustment can be selected. The front caster angle is adjustable, allowing a wide combination of seat heights and seat angles to support all types of wheelchair users. The wheelchair is constructed from high-strength aluminium tubing with reinforced side frames to ensure a stable connection for the PAWS Power Add-Ons and TRACK WHEEL.

### FEATURES AT A GLANCE

- Self and attendant propelled
- Various adjustment possibilities
- Center of gravity adjustable
- Rear wheels with 2 degrees camber
- Foldable handles
- Fixed leg rests

### COLOUR: Black matt

#### HMV number: requested

Weight (Seat width 45 cm)	Transport Weight	<b>SWL</b> (Safe Weight Limit)	Seat widths	Seat depths	Front seat height	Rear seat height	Backrest height	Wheelchair height	Width folded	Total width	Footrest angle (in leg)	Front caster wheels	Rear wheels
13 kg	8,5 kg	125 kg	40 or 45 cm	40 or 45 cm	43,5 - 48,5 cm	39 - 45,5 cm	31 or 34 cm	83 or 86 cm	35 cm	63 or 68 cm	80°	5"/ 125 mm	24" x 1"

**TECHNICAL DATA** 



Tension adjustable back straps



Anti-tip available as an accessory

### SOME IMPORTANT DETAILS



Height adjustable and removable armrests



Length adjustable footplates



Lightweight wheels 24" x 1" incl. high pressure tire



ICON 30 FAF with TRACK WHEEL (only for the Double Arm version)



ICON 30 FAF is the ideal wheelchair for use with PAWS

F	Ø	$\mathbf{\mathbf{e}}$	in
	Your Rehase	ense Dealer	
			V1-2023

Rehasense's quality management complies with both the ISO 9001 and ISO 13485 standards, as confirmed by TÜV NORD. Rehasense's medical devices are CE-marked and meet the requirements of EU Regulation 2017/745 (MDR).